Skye Bioscience, Inc. (SKYE) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2020
Loading P/E history...
SKYE Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Skye Bioscience, Inc. (SKYE) trades at a price-to-earnings ratio of -0.6x, with a stock price of $0.90 and trailing twelve-month earnings per share of $-1.41.
The current P/E is 152% below its 5-year average of 1.2x. Over the past five years, SKYE's P/E has ranged from a low of 0.4x to a high of 2.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SKYE trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SKYE trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SKYE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SKYE P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $358B | 85.5 | -Best | -1%Best | |
| $151B | 19.5Lowest | -Best | -4% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SKYE Historical P/E Data (2019–2020)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $10.50 | $27.74 | 0.4x | -69% |
| FY2020 Q2 | $39.25 | $19.00 | 2.1x | +69% | |
| FY2020 Q1 | $18.75 | $41.50 | 0.5x | -63% | |
| FY2019 Q4 | $32.75 | $16.50 | 2.0x | +63% |
Average P/E for displayed period: 1.2x
See SKYE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKYE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKYE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSKYE — Frequently Asked Questions
Quick answers to the most common questions about buying SKYE stock.
Is SKYE stock overvalued or undervalued?
SKYE trades at -0.6x P/E, below its 5-year average of 1.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SKYE's valuation compare to peers?
Skye Bioscience, Inc. P/E of -0.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SKYE's PEG ratio?
SKYE PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2020.